Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carbox amides and of 4-oxo-3,4-dihydroquinazoline-8-carboxa mides, preparation thereof and application thereof in therapeutics

Details for Australian Patent Application No. 2008306762 (hide)

Owner SANOFI-AVENTIS

Inventors Malleron, Jean-Luc; Evers, Michel; Karlsson, Andreas; Genevois-Borella, Arielle

Agent A J Park

Pub. Number AU-A-2008306762

PCT Pub. Number WO2009/044018

Priority 0705500 27.07.07 FR

Filing date 25 July 2008

Wipo publication date 9 April 2009

International Classifications

A61K 31/472 (2006.01) - Non-condensed isoquinolines, e.g. papaverine

A61K 31/498 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 35/00 (2006.01) Antineoplastic agents

C07D 217/24 (2006.01) Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems

C07D 239/88 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

Event Publications

25 February 2010 PCT application entered the National Phase

  PCT publication WO2009/044018 Priority application(s): WO2009/044018

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008306763-1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5carboxamide derivatives, preparation and therapeutic use thereof

2008306755-Use of at least one oxime derivative of 3,5-seco-4-norcholestane as antioxidants